These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15179021)

  • 1. Decreased plasma antioxidants in schizophrenia.
    Pae CU; Paik IH; Lee C; Lee SJ; Kim JJ; Lee CU
    Neuropsychobiology; 2004; 50(1):54-6. PubMed ID: 15179021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study.
    Nakano Y; Yoshimura R; Nakano H; Ikenouchi-Sugita A; Hori H; Umene-Nakano W; Ueda N; Nakamura J
    Hum Psychopharmacol; 2010 Mar; 25(2):139-44. PubMed ID: 20196178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased plasma antioxidants in patients with Alzheimer's disease.
    Kim TS; Pae CU; Yoon SJ; Jang WY; Lee NJ; Kim JJ; Lee SJ; Lee C; Paik IH; Lee CU
    Int J Geriatr Psychiatry; 2006 Apr; 21(4):344-8. PubMed ID: 16534775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment.
    Cai HL; Fang PF; Li HD; Zhang XH; Hu L; Yang W; Ye HS
    Psychiatry Res; 2011 Jul; 188(2):197-202. PubMed ID: 21146875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
    Glenthoj A; Glenthoj BY; Mackeprang T; Pagsberg AK; Hemmingsen RP; Jernigan TL; Baaré WF
    Psychiatry Res; 2007 Apr; 154(3):199-208. PubMed ID: 17360162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone in first-episode schizophrenia.
    Cesková E; Prikryl R; Kaspárek T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
    Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone.
    Cai HL; Li HD; Yan XZ; Sun B; Zhang Q; Yan M; Zhang WY; Jiang P; Zhu RH; Liu YP; Fang PF; Xu P; Yuan HY; Zhang XH; Hu L; Yang W; Ye HS
    J Proteome Res; 2012 Aug; 11(8):4338-50. PubMed ID: 22800120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
    Lee BH; Kim YK
    Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia.
    Song XQ; Lv LX; Li WQ; Hao YH; Zhao JP
    Biol Psychiatry; 2009 Mar; 65(6):481-8. PubMed ID: 19058794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study.
    Veznedaroglu B; Ercan ES; Kayahan B; Varan A; Bayraktar E
    Hum Psychopharmacol; 2003 Dec; 18(8):635-40. PubMed ID: 14696023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R; Nakamura J; Shinkai K; Goto M; Yamada Y; Kaji K; Kakihara S; Ueda N; Kohara K; Ninomiya H; Egami H; Maeda H
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gilbert's syndrome and schizophrenia].
    Molina Ramos R; Villanueva Curto S; Molina Ramos JM
    Actas Esp Psiquiatr; 2006; 34(3):206-8. PubMed ID: 16736395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
    Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
    J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in heart rate dynamics of patients with schizophrenia treated with risperidone.
    Chang JS; Yoo CS; Yi SH; Hong KH; Lee YS; Oh HS; Jung DC; Kim YS; Ahn YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):924-9. PubMed ID: 20423720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.